virus (EBV) establishes a latent, life-long infection in more than 95% of the human adult population. Antigen-specific, cytolytic T lymphocytes (CTLs) are thought to be of central importance in controlling EBV in both primary and latent infection states. While a good deal is known about the CTL dynamics during primary infection and convalescence, [1] [2] [3] [4] little is known about the CTL repertoire during the decades of infection after first contact. For example, do CTL clones persist indefinitely throughout an individual's lifetime or do new naive T-cell expansions emerge to help refresh the repertoire? We addressed this question by investigating the CTL dynamics toward immunodominant EBV epitopes up to 18 years apart, which is, to our knowledge, the longest follow-up study of T-cell responses conducted in humans.
from 1994 and 2005 ( Figure 1B ). Like the FLR-specific repertoire in donor 1, the donor 2 EEN-specific repertoire consisted of a single, nucleotide-identical TRBV7-8/TRAV26 expansion. In addition, the clonal donor 2 EEN-specific expansion appeared to increase in frequency with time ( Figure 1C ). This observation in the donor, aged 61 years in 2005, is consistent with a previous study showing virus-specific CTLs sometimes increasing with age. 11 This study follows the CTL response toward two immunodominant class I-binding EBV epitopes over a period of 18 or 11 years. Remarkably, we found no evidence of perturbations in the T-cell hierarchy over time, with both clonal CTL expansions remaining unchanged. Overall, the study provides an important advance in understanding the longevity and stability of the T-cell repertoire toward a persistent pathogen. Indeed, these findings suggest the likely situation of a single naive T-cell expansion facilitating the control of a persistent viral infection for the entire span of a human life. To the editor:
The role of duodenal cytochrome b in intestinal iron absorption remains unclear
Duodenal cytochrome b (Dcytb; encoded by the Cybrd1 gene), a ferric reductase expressed at the brush border of duodenal enterocytes, 1 has been proposed to reduce dietary ferric iron, thereby facilitating its transport into the mucosal cells by the ferrous iron transporter divalent metal transporter 1. To define the role of Dcytb in intestinal iron absorption, Gunshin et al 2 have taken the important step of generating a Dcytb knockout mouse. From their analysis of the hepatic iron levels of these animals, they concluded that Dcytb is not necessary for dietary iron absorption in mice. However, this conclusion should be interpreted with caution, as no direct measurements of iron absorption were made and the reliance on liver iron levels does not provide unequivocal evidence for or against an absorption defect. The authors show that Cybrd1 Ϫ/Ϫ mice maintained on standard rodent chow have hepatic iron levels similar to wild-type mice, and at face value this would suggest that Dcytb plays no role in iron absorption under normal conditions. However, the diet used for these studies (Prolab RMH 3000 LabDiet; PMI Richmond, Richmond, IN) contains a large amount of iron (380 mg/kg), including added ferrous iron, and thus both wild-type and Cybrd1 Ϫ/Ϫ mice would likely absorb comparable quantities of iron as the ferric iron reduction step is bypassed. Thus the results obtained are not unexpected. To adequately define the role of Dcytb, direct iron absorption studies should be carried out or the mice should be maintained on a diet containing ferric iron only. The former approach is preferable.
In the second part of the study, animals were maintained on an iron-deficient diet to determine whether Dcytb plays a role in absorption when iron is limiting. Liver iron content was measured and found to be similar in both Cybrd1 Ϫ/Ϫ mice and controls. As iron absorption was not measured, this experiment gives no information about the role of Dcytb in absorption and simply shows that liver iron stores in both strains of mice decrease when the amount of iron in the diet is low. To demonstrate this point, we present comparable data from the sla mouse. These animals carry a deletion in the Heph gene (which encodes the ferroxidase hephaestin) 3 and have defective basolateral export of iron from intestinal enterocytes. 4 When sla mice and control animals are placed on an iron-deficient diet for 6 weeks there is no difference in their liver iron content (Figure 1 ), similar to the results presented for the Cybrd1 Ϫ/Ϫ mouse. However, when intestinal iron absorption was measured in these animals we found that sla mice had a significantly lower absorption than control mice (Figure 1 ). This clearly shows that liver iron levels cannot be used as a surrogate marker of iron absorption under these conditions. We believe that the question of whether Dcytb plays a role in iron absorption remains unresolved. Only direct measurements of iron absorption using radioactive ferric iron in knockout and control animals, maintained on both standard and iron-deficient diets, will answer this question definitively. Intestinal iron absorption and liver iron content in sla and C57BL/6J mice on an iron-deficient diet. Animals were maintained on an iron-deficient diet for 6 weeks from weaning, and iron absorption was determined by whole-body counting following the oral administration of radioactive iron as previously described. 5 Absorption (f) is presented as the percentage of the initial iron dose retained by the animals 5 days after dosing. Hepatic iron measurements (Ⅺ) were performed on liver tissue as previously described. 6 Data represent the mean Ϯ SEM of 3 animals. Statistical differences were assessed using Student t test. P ϭ .001 for iron absorption. P ϭ .86 for liver iron content.
